hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06382181, orgStudyIdInfo id: 2023- ENFPOD-2621979, secondaryIdInfos id: Silvia Corchón Arreche, type: OTHER, domain: University of Valencia, secondaryIdInfos id: Omar Cauli, type: OTHER, domain: University of Valencia, briefTitle: A Multimodal Intervention for Community-dwelling Individuals With Unwanted Loneliness, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-04-01, primaryCompletionDateStruct date: 2023-07-01, completionDateStruct date: 2023-07-31, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: University of Valencia, class: OTHER, descriptionModule briefSummary: The absence of social relationships negatively affects physical, psychological, and social health. In other words, it alters people's quality of life and makes active aging difficult. The investigators have designed a study to reduce unwanted loneliness in people over 65 living in the community through multiple interventions (music therapy, health education, and physical exercise)., conditionsModule conditions: Loneliness, conditions: Mental Health Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Participants were assigned to three groups in parallel for the duration of the study, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ACTUAL, armsInterventionsModule interventions name: Music therapy for community-dwelling individuals with unwanted loneliness, interventions name: Health education for community-dwelling individuals with unwanted loneliness, interventions name: Physical exercise for community-dwelling individuals with unwanted loneliness, outcomesModule primaryOutcomes measure: Score on the Jong Gierveld Loneliness Scale, secondaryOutcomes measure: Score on Goldberg Anxiety and Depression Scale, eligibilityModule sex: ALL, minimumAge: 60 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Valencia, city: Valencia, zip: 46010, country: Spain, geoPoint lat: 39.46975, lon: -0.37739, locations facility: Vanessa Ibáñez del Valle, city: Valencia, zip: 46010, country: Spain, geoPoint lat: 39.46975, lon: -0.37739, hasResults: False
protocolSection identificationModule nctId: NCT06382142, orgStudyIdInfo id: BL-B01D1-307, briefTitle: A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2026-05, completionDateStruct date: 2026-05, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Sichuan Baili Pharmaceutical Co., Ltd., class: INDUSTRY, collaborators name: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd., descriptionModule briefSummary: This trial is a registered phase III, randomized, open-label, multicenter study designed to evaluate the efficacy and safety of BL-B01D1 in patients with unresectable locally advanced or metastatic Triple-Negative breast cancer after taxane failure., conditionsModule conditions: Triple-Negative Breast Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 436, type: ESTIMATED, armsInterventionsModule interventions name: BL-B01D1, interventions name: Eribulin, interventions name: Vinorelbine, interventions name: Gemcitabine, interventions name: Capecitabine, outcomesModule primaryOutcomes measure: Progression-free survival (PFS), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: Objective Response Rate (ORR), secondaryOutcomes measure: Disease Control Rate (DCR), secondaryOutcomes measure: Duration of Response (DOR), secondaryOutcomes measure: Treatment Emergent Adverse Event (TEAE), secondaryOutcomes measure: Anti-drug antibody (ADA), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fudan University Shanghai Cancer Center, city: Shanghai, state: Shanghai, country: China, contacts name: Jiong Wu, role: CONTACT, contacts name: Jiong Wu, role: PRINCIPAL_INVESTIGATOR, contacts name: Jian Zhang, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06382129, orgStudyIdInfo id: BL-B01D1-302, briefTitle: A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2026-05, completionDateStruct date: 2026-05, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Sichuan Baili Pharmaceutical Co., Ltd., class: INDUSTRY, collaborators name: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd., descriptionModule briefSummary: This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with locally advanced or metastatic EGFR wild-type non-small cell lung cancer after failure of anti-PD-1/PD-L1 monoclonal antibodies and platinum-based chemotherapy., conditionsModule conditions: Non-small Cell Lung Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 558, type: ESTIMATED, armsInterventionsModule interventions name: BL-B01D1, interventions name: Docetaxel, outcomesModule primaryOutcomes measure: Overall survival (OS), primaryOutcomes measure: Progression-free survival (PFS), secondaryOutcomes measure: Objective Response Rate (ORR), secondaryOutcomes measure: Disease Control Rate (DCR), secondaryOutcomes measure: Duration of Response (DOR), secondaryOutcomes measure: Treatment Emergent Adverse Event (TEAE), secondaryOutcomes measure: Anti-drug antibody (ADA), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Cancer Hospital Chinese Academy of Medical Sciences, city: Beijing, state: Beijing, country: China, contacts name: Jie Wang, role: CONTACT, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06382116, orgStudyIdInfo id: BL-B01D1-301, briefTitle: A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2026-05, completionDateStruct date: 2026-05, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Sichuan Baili Pharmaceutical Co., Ltd., class: INDUSTRY, collaborators name: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd., descriptionModule briefSummary: This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with locally advanced or metastatic non-squamous non-small cell lung cancer with EGFR-sensitive mutations after EGFR-TKI failure., conditionsModule conditions: Non-small Cell Lung Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 428, type: ESTIMATED, armsInterventionsModule interventions name: BL-B01D1, interventions name: Pemetrexed+Cisplatin or Carboplatin, outcomesModule primaryOutcomes measure: Progression-free survival (PFS), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: Objective Response Rate (ORR), secondaryOutcomes measure: Disease Control Rate (DCR), secondaryOutcomes measure: Duration of Response (DOR), secondaryOutcomes measure: Treatment Emergent Adverse Event (TEAE), secondaryOutcomes measure: Anti-drug antibody (ADA), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Sun Yat-sen University Cancer Center, city: Guangzhou, state: Guangdong, country: China, contacts name: Li Zhang, role: CONTACT, geoPoint lat: 23.11667, lon: 113.25, hasResults: False
protocolSection identificationModule nctId: NCT06382103, orgStudyIdInfo id: B2024-108R, briefTitle: Biomarkers and Molecular Mechanism Study of Hepatocellular Carcinoma After Radical Resection and Conversion Therapy, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-20, primaryCompletionDateStruct date: 2025-05-20, completionDateStruct date: 2026-05-20, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Shanghai Zhongshan Hospital, class: OTHER, descriptionModule briefSummary: Blood samples will be tested to identify circulating tumor DNA and plasma protein levels to potentially improve prediction of long term prognosis and guide treatment options of patients with hepatocellular carcinoma underwent surgical resection., conditionsModule conditions: Hepatocellular Carcinoma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule interventions name: ctDNA monitoring, interventions name: Plasma proteomic analysis, outcomesModule primaryOutcomes measure: Correlation between ctDNA level and recurrence-free survival (RFS), primaryOutcomes measure: Correlation between specific plasma protein expression level and recurrence-free survival (RFS), secondaryOutcomes measure: Correlation between tumor mutation numbers and recurrence-free survival (RFS), eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: 180 Fenglin Road, city: Shanghai, zip: 200032, country: China, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06382090, orgStudyIdInfo id: PamukkaleU-SBE-BB-01, briefTitle: Premenstrual Syndrome and Laughter Yoga, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-26, primaryCompletionDateStruct date: 2024-05-24, completionDateStruct date: 2025-05-24, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Pamukkale University, class: OTHER, descriptionModule briefSummary: In addition to physical and emotional effects, premenstrual syndrome can negatively affect the participation in classes, school success, social activities and family relationships of young adolescents in high school. Many non-pharmacological treatments have been found to improve premenstrual syndromes in adolescents. Laughter yoga, one of these methods, is a practice consisting of deep breathing exercises and laughter exercises. Laughter yoga has been studied in different sample groups (elderly people, nurses, dialysis patients, etc.) and positive results have been obtained. In this study, the effect of laughter yoga on premenstrual symptoms in adolescents will be examined., conditionsModule conditions: Premenstrual Syndrome, conditions: Laughter, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Two groups: comparative experiment and control, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 68, type: ESTIMATED, armsInterventionsModule interventions name: Laughter yoga, outcomesModule primaryOutcomes measure: Premenstrual Symptom Scale, eligibilityModule sex: FEMALE, minimumAge: 12 Years, maximumAge: 17 Years, stdAges: CHILD, hasResults: False
protocolSection identificationModule nctId: NCT06382077, orgStudyIdInfo id: CPSP5502, briefTitle: Chronic Post Surgical Pain-Cardiac, acronym: CPSP-Cardiac, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-25, primaryCompletionDateStruct date: 2025-04-25, completionDateStruct date: 2025-10-25, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Ondokuz Mayıs University, class: OTHER, descriptionModule briefSummary: The CPSP-Cardiac is a large, multi-center, observational study with the aim to investigate the incidence of chronic pain in the 3rd month postoperatively in cardiac surgery and its affecting factors., conditionsModule conditions: Chronic Post-surgical Pain, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 1176, type: ESTIMATED, outcomesModule primaryOutcomes measure: The incidence of chronic postsurgical pain, secondaryOutcomes measure: Postoperative opioid consumption in the first 24 hours, secondaryOutcomes measure: Postoperative pain scores, secondaryOutcomes measure: The incidences of postoperative nausea and vomiting, secondaryOutcomes measure: The number of patients with side effects and complications, secondaryOutcomes measure: Time to extubation, secondaryOutcomes measure: Length of stay in the intensive care unit, secondaryOutcomes measure: Length of stay in the hospital, secondaryOutcomes measure: Chronic pain status at 3 and 6 months, secondaryOutcomes measure: Psychological assessment, secondaryOutcomes measure: Quality of life assessment, secondaryOutcomes measure: Postoperative complications at 3 and 6 months, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ondokuz Mayis University, city: Samsun, state: Atakum, zip: 55139, country: Turkey, geoPoint lat: 41.27976, lon: 36.3361, locations facility: Istanbul University, city: Istanbul, country: Turkey, contacts name: Zerrin Sungur, role: CONTACT, geoPoint lat: 41.01384, lon: 28.94966, locations facility: Marmara University, city: Istanbul, country: Turkey, contacts name: Alper Kararmaz, role: CONTACT, geoPoint lat: 41.01384, lon: 28.94966, locations facility: Burhan Dost, city: Samsun, zip: 55270, country: Turkey, contacts name: BURHAN DOST, role: CONTACT, phone: 05327042493, email: burhandost@hotmail.com, geoPoint lat: 41.27976, lon: 36.3361, hasResults: False
protocolSection identificationModule nctId: NCT06382064, orgStudyIdInfo id: 2024H0089, briefTitle: Evaluation of Wear Experience With One Week Reusable Contact Lenses in Habitual Two Week Reusable Lens Wearers, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-04-16, primaryCompletionDateStruct date: 2024-09, completionDateStruct date: 2025-05, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Ohio State University, class: OTHER, descriptionModule briefSummary: This open-label study is of current Acuvue® Oasys® wearers (2 - week replacement, reusable lenses) who are satisfied with their current lenses. Subjects will be refit into one week reusable contact lenses and will wear lenses for approximately 2 weeks. Subjects will return for vision and lens fit assessments and will complete surveys about their wear experience., conditionsModule conditions: Myopia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Subjects will be fit into Acuvue Oasys contact lenses at the first visit to wear for 2 weeks. Subjects will then be fit into PRECISION7 lenses at the second visit to wear for 2 weeks., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Biweekly replacement contact lenses, interventions name: One week replacement contact lenses, outcomesModule primaryOutcomes measure: Subjective assessment of lens wear experience, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The Ohio State University College of Optometry, city: Columbus, state: Ohio, zip: 43210, country: United States, geoPoint lat: 39.96118, lon: -82.99879, hasResults: False
protocolSection identificationModule nctId: NCT06382051, orgStudyIdInfo id: CAIN457ACA06, briefTitle: Modifying PEST for Psoriatic Arthritis Screening, acronym: ScreenX, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-28, primaryCompletionDateStruct date: 2025-04-30, completionDateStruct date: 2025-04-30, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Novartis Pharmaceuticals, class: INDUSTRY, descriptionModule briefSummary: The purpose of this study is to assess the impact of adding two questions and pictures to the validated PEST on the potential diagnosis of PsA in participants with moderate-to-severe plaque PsO in Canada.Patients will be enrolled in the study for up to 66 days and will be asked to fill-out a PsA screening questionnaire at their first dermatologist visit. Patients screening positive for PsA will have a second visit with a rheumatologist where a full PsA diagnosis assessment will be performed. A remote 'end of study' (EOS) visit will be conducted by the dermatologist to document the patient's biologic Disease-Modifying Antirheumatic Drugs (bDMARDs) treatment choice and status., conditionsModule conditions: Plaque Psoriasis, conditions: Psoriatic Arthritis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: SCREENING, maskingInfo masking: NONE, enrollmentInfo count: 502, type: ESTIMATED, armsInterventionsModule interventions name: PEST Screening group, outcomesModule primaryOutcomes measure: Positive Predictive Value (PPV) for PEST and PEST+2 in adult patients with moderate-to-severe plaque PsO who are candidates for bDMARDs, secondaryOutcomes measure: Proportion of patients scoring negative on PEST and positive on PEST+2 with a confirmed new PsA diagnosis or suspicion of PsA by a rheumatologist, secondaryOutcomes measure: Proportion of patients with a confirmed new PsA diagnosis or suspicion of PsA by a rheumatologist, secondaryOutcomes measure: Proportion of patients with a false positive score between each group, secondaryOutcomes measure: Description of the baseline characteristics of the positive screening score and negative screening score patients for both PEST and PEST+2 tests, secondaryOutcomes measure: Patient acceptability/user experience of the PEST+2 questionnaire, secondaryOutcomes measure: Administration of dermatologist quantitative surveys, secondaryOutcomes measure: Qualitative interview with selected dermatologists, secondaryOutcomes measure: Intervention Appropriateness Measure (IAM), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 99 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06382038, orgStudyIdInfo id: HZKY-PJ-2024-19, briefTitle: Smart Technology Facilitated Patient-centered Care for Patients With Pulmonary Thromboembolism, acronym: SmaPE, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2026-10-31, completionDateStruct date: 2026-10-31, studyFirstPostDateStruct date: 2024-04-24, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Navy General Hospital, Beijing, class: OTHER, descriptionModule briefSummary: Smart technologies, such as wearable devices, mobile technologies, and artificial intelligence, are being investigated for use in health management. These technologies have the potential to be applied in disease pre-warning, decision-making support, health education, and healthcare maintenance. They are expected to address the challenges in managing thrombosis, improve access to high-quality medical resources in various regions, and enhance the development of a network for thrombosis rescue and treatment prevention.The objective of this study is to evaluate the impact of mobile venous thromboembolism application (mVTEA) based patient-centered management of pulmonary thromboembolism (PTE) on the long-term outcome of PTE patients, in order to enhance clinical practice and establish a foundation of evidence for managing patients with PTE., conditionsModule conditions: Venous Thromboembolism, conditions: Pulmonary Thromboembolisms, conditions: Clinical Decision Support Systems, conditions: Digital Health, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: TRIPLE, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 3078, type: ESTIMATED, armsInterventionsModule interventions name: mobile venous thromboembolism application (mVTEA), outcomesModule primaryOutcomes measure: VTE-related composite event, secondaryOutcomes measure: Patient satisfaction with anticoagulant treatment, secondaryOutcomes measure: Generic quality of life, secondaryOutcomes measure: Recurrent VTE, secondaryOutcomes measure: Chronic thromboembolic pulmonary hypertension (CTEPH), secondaryOutcomes measure: Major bleeding, secondaryOutcomes measure: VTE-related hospitalization, secondaryOutcomes measure: Death, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Sixth Medical Center of Chinese PLA General Hospital, city: Beijing, state: Beijing, zip: 100048, country: China, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False